Generic Name: carfilzomib (kar FILZ oh mib)
Brand Names: Kyprolis
Medically reviewed on Nov 1, 2018
What is Kyprolis?
Kyprolis (carfilzomib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Kyprolis is used to treat multiple myeloma. It is sometimes given with other medicines when treating relapsed multiple myeloma.
Kyprolis is usually given after other treatments have failed.
Kyprolis can affect your heart or lungs. Call your doctor at once if you have chest pain, pounding heartbeats, shortness of breath (even with mild exertion or while lying down), swelling of your hands or feet, feeling like you might pass out, wheezing, gasping for breath, cough with foamy mucus, or blue colored appearance of your lips and skin.
Before taking this medicine
You should not use Kyprolis if you are allergic to carfilzomib.
To make sure this medicine is safe for you, tell your doctor if you have:
kidney disease (or if you are on dialysis);
heart disease, high blood pressure; or
Kyprolis can harm an unborn baby or cause birth defects if the mother or the father is using this medicine.
If you are a woman, do not use Kyprolis if you are pregnant. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 30 days after your last dose.
If you are a man, use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 90 days after your last dose.
Tell your doctor right away if a pregnancy occurs while either the mother or the father is using Kyprolis.
You should not breast-feed while using carfilzomib.
How is Kyprolis given?
Kyprolis is given as an infusion into a vein. A healthcare provider will give you this injection.
Kyprolis is given in a 28-day treatment cycle. You will receive an injection only on certain days of this cycle.
Drink plenty of liquids before and after your injections.
You may be given other medications to help prevent serious side effects or infections. Keep using these medicines for as long as your doctor has prescribed.
You may need frequent medical tests to be sure this medicine is not causing harmful effects. Your cancer treatments may be delayed based on the results.
Kyprolis dosing information
Usual Adult Dose OF Kyprolis for Multiple Myeloma:
Initial (Cycle 1): 20 mg/m2 intravenously, over 2 to 10 minutes, on the first two days of each treatment week for 3 weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12 day rest period (Days 17 to 28).
Maintenance: 27 mg/m2 intravenously, beginning in Cycle 2, if Cycle 1 dose was tolerated, and continuing for subsequent cycles, as tolerated. The dosing schedule remains the same for Cycle 2 and subsequent cycles.
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your Kyprolis injection.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
What should I avoid while receiving Kyprolis?
Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired.
This medicine can pass into body fluids (urine, feces, vomit). For at least 48 hours after you receive a dose, avoid allowing your body fluids to come into contact with your hands or other surfaces. Caregivers should wear rubber gloves while cleaning up a patient's body fluids, handling contaminated trash or laundry or changing diapers. Wash hands before and after removing gloves. Wash soiled clothing and linens separately from other laundry.
Kyprolis side effects
Get emergency medical help if you have signs of an allergic reaction to Kyprolis: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur within 24 hours after the injection. Tell your caregiver right away if you feel dizzy, weak, nauseated, light-headed, feverish, sweaty, or if you have joint or muscle pain, a headache, chest tightness, back pain, trouble breathing, or swelling in your face.
Call your doctor at once if you have:
shortness of breath (even while lying down), wheezing, blue colored lips and skin, cough with foamy mucus;
a light-headed feeling, like you might pass out;
easy bruising, unusual bleeding, or any bleeding that will not stop;
headache, confusion, change in mental status, vision loss, seizure (convulsions);
vomiting, diarrhea, weakness, blood in your stools, coughing up blood or vomit that looks like coffee grounds;
jaundice (yellowing of the skin or eyes);
heart problems - chest pain, pain spreading to your jaw or shoulder, pounding in your neck or ears, blurred vision, anxiety;
kidney problems - little or no urination, swelling in your feet or ankles, feeling tired or short of breath;
low blood cell counts - fever, chills, tiredness, mouth sores, skin sores, pale skin, cold hands and feet;
low potassium level - leg cramps, irregular heartbeats, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling;
signs of a blood clot - sudden numbness or weakness, slurred speech, pain or redness in an arm or leg; or
Common Kyprolis side effects may include:
fever, bruising, pale skin or other signs of low blood cell counts;
swelling in your hands or feet; or
headache, trouble sleeping, feeling tired.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect Kyprolis?
Other drugs may interact with carfilzomib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Kyprolis only for the indication prescribed.
Copyright 1996-2018 Cerner Multum, Inc. Version: 3.02.
More about Kyprolis (carfilzomib)
- Kyprolis Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- 2 Reviews
- Drug class: proteasome inhibitors